Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC): 2 pipeline candidates · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.7 months
D/E 1.59 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Fibrocell Science, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$6.8M
Quarterly Burn
$6.6M
Runway
4.7 mo
Revenue
$1.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Fibrocell Science, Inc.'s pipeline?
Fibrocell Science, Inc. (FCSC) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Fibrocell Science, Inc.'s lead drug candidate?
Fibrocell Science, Inc.'s most advanced tracked candidate is fcx-007 (Phase 1/Phase 2) for recessive dystrophic epidermolysis bullosa (RDEB).
What is Fibrocell Science, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Fibrocell Science, Inc. has approximately 4.7 months of cash runway.
Who is the CEO of Fibrocell Science, Inc.?
Important Notice Regarding is the chief executive officer of Fibrocell Science, Inc. (FCSC).
Get the full picture on Fibrocell Science, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.